-
Does every enhancer work with every promoter?
An enhancer × promoter MPRA, rebuilt to remove assay confounders, shows that promoters differ more than 100-fold in their intrinsic responsiveness to enhancers — reconciling a long-standing contradiction in the field.
-
Why guinea pigs grow natural bypass arteries — and how we might too
An in vivo Perturb-seq screen, guided by the differences between species, uncovers the pathways that build protective collateral arteries.
-
The hidden catch in CRISPR-Cas13d screens for functional circular RNAs
Junction-targeting Cas13d guides often knock down the linear mRNA too — so many 'functional circRNA' hits may be off-target artifacts. A cautionary re-analysis, now in Nucleic Acids Research.
-
What we learn by CRISPR'ing a random set of regulatory elements
An unbiased CRISPRi survey of ~1,000 randomly chosen accessible sites — and a new toolkit (DC-TAP-seq) for measuring enhancer effects on gene expression.
-
The E2G Portal: enhancer–gene predictions across 1,600+ cell types
A major milestone in mapping enhancers and interpreting variants — browse our enhancer-gene predictions across more than 1,600 cell types and tissues at e2g.stanford.edu.
-
Rewriting regulatory DNA to dissect and reprogram gene expression
Variant-EFFECTS uses high-throughput prime editing, flow sorting, and sequencing to precisely measure how noncoding variants change gene expression — now in Cell.
-
What cell types drive congenital heart defects?
A single-cell multiomic atlas of 734,000 cells from 41 fetal hearts — and what it reveals about the cell types and noncoding variants behind congenital heart disease.
-
scE2G: linking enhancers to their target genes from single-cell data
A new model that uses single-cell data to connect enhancers to the genes they regulate — a step toward building enhancer maps across hundreds of human cell types.